The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis
Madeline L Kelly, Arseniy Lavrov, Luis Garcia‐Gancedo, Jim Parr, Robert G. Hart, Theresa Chiwera, Christopher E. Shaw, Ammar Al‐Chalabi, Rachael Marsden, Martin R. Turner, Kevin Talbot
Abstract
OBJECTIVE: Biotelemetry measures of physical activity in this Pilot Study tracked ALS progression over time, highlighting their potential as endpoints for future clinical trials. A larger, formally powered study is required to further support activity endpoints as novel disease progression markers.
Topics & Concepts
Amyotrophic lateral sclerosisMedicineBiotelemetryPhysical therapyRating scaleInternal medicineClinical trialAdverse effectClinical endpointPhysical medicine and rehabilitationExpanded Disability Status ScaleQuality of life (healthcare)DiseaseMultiple sclerosisPsychologyTelemetryEngineeringDevelopmental psychologyAerospace engineeringPsychiatryNursingAmyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders ResearchParkinson's Disease Mechanisms and Treatments